Antiviral Therapy Trial for Parkinson's Disease

Antiviral Therapy Trial Design for Parkinson's Disease (Viral Trigger Hypothesis)

Experiment Overview

This experiment tests the Viral Trigger Hypothesis in Parkinson's disease by evaluating whether antiviral therapy (valacyclovir) reduces herpes simplex virus type 1 (HSV-1) reactivation events and slows disease progression in early-stage PD patients.

Hypothesis Being Tested

Antiviral Therapy Trial Design for Parkinson's Disease (Viral Trigger Hypothesis)

Experiment Overview

This experiment tests the Viral Trigger Hypothesis in Parkinson's disease by evaluating whether antiviral therapy (valacyclovir) reduces herpes simplex virus type 1 (HSV-1) reactivation events and slows disease progression in early-stage PD patients.

Hypothesis Being Tested

Primary Hypothesis: Chronic/repeated HSV-1 reactivation in the peripheral and central nervous system contributes to neuroinflammation and dopaminergic neurodegeneration in PD. Suppressing viral reactivation with antiviral therapy will reduce inflammatory burden and slow disease progression.

Secondary Hypotheses:

Study Design

Type

Population

• Sample size: 200 participants (100 per arm)
• Age: 50-75 years
• Disease stage: Early PD (Hoehn-Yahr 1-2.5)
• Disease duration: ≤3 years from diagnosis
• MMSE: ≥26 (no significant cognitive impairment)

Inclusion Criteria

Exclusion Criteria

Intervention

Treatment Arm

• Drug: Valacyclovir (1g twice daily)
• Duration: 12 months
• Rationale: Valacyclovir is a prodrug of acyclovir with better oral bioavailability; suppresses HSV-1 replication and reduces reactivation frequency

Control Arm

• Drug: Placebo (matched tablets)
• Duration: 12 months

Endpoints

Primary Endpoints

Secondary Endpoints

Safety Endpoints

• Adverse events (AE/SAE) monitoring
• Liver function tests (ALT, AST)
• Renal function (creatinine, eGFR)
• Complete blood count

Statistical Analysis

Primary Analysis

• Intent-to-treat population
• Mixed-effects model for repeated measures (MMRM)
• Treatment effect on UPDRS-III change from baseline
• Adjustment for baseline covariates: age, disease duration, baseline UPDRS

Sample Size Calculation

• Expected treatment effect: 3 points difference in UPDRS-III (SD=8)
• Power: 80%
• Alpha: 0.05 (two-sided)
• 20% attrition adjustment

Secondary Analyses

• Per-protocol analysis
• Subgroup analyses by baseline HSV-1 titer
• Correlation: HSV-1 avidity vs. UPDRS change
• Correlation: inflammatory markers vs. UPDRS change

Safety Monitoring

Data Safety Monitoring Board (DSMB)

• Reviews unblinded safety data every 3 months
• Stopping rules: >5% serious adverse events in treatment arm

Adverse Event Reporting

• Expected: mild GI symptoms, headache
• Unexpected: severe cutaneous reactions, hepatic toxicity

Budget Estimate

| Item | Cost (USD) |
|------|-----------|
| Study coordination | 00,000 |
| Drug/placebo | 00,000 |
| Lab assays | 00,000 |
| Imaging (DaTSPECT) | 00,000 |
| Statistical analysis | 50,000 |
| Regulatory/IRB | 0,000 |
| Contingency (15%) | 80,000 |
| Total | ,380,000 |

Timeline

| Milestone | Month |
|-----------|-------|
| Protocol finalization | 0 |
| IRB submission/approval | 1-3 |
| Patient enrollment | 3-15 |
| Follow-up completion | 15-27 |
| Data analysis | 27-30 |
| Publication | 30-36 |

Ethical Considerations

• Informed consent from all participants
• Minimal risk design (valacyclovir is FDA-approved with known safety profile)
• Independent DSMB oversight
• Results will be shared regardless of outcome

Expected Outcomes

If Hypothesis Supported

• Significant reduction in UPDRS-III progression in treatment arm
• Decreased HSV-1 reactivation markers
• Reduced inflammatory biomarkers
• Supports clinical trial progression to Phase 3

If Hypothesis Not Supported

• No difference between arms
• Inflammatory markers unchanged
• Will inform future research directions

See Also

• [Experiment Index](/experiments/experiment-index)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

[@olsen2023]: [Olsen et al., Antiviral therapy and neuroinflammation (2023)](https://doi.org/10.1093/femsre/fuad043)

Pathway Diagram

The following diagram shows the key molecular relationships involving Antiviral Therapy Trial for Parkinson's Disease discovered through SciDEX knowledge graph analysis: